Future studies involving a larger Alpers' syndrome patient cohort, an array of mitochondrial disease encephalopathies and nonprimary mitochondrial epilepsies should be performed to further explore the differential vulnerability of parvalbumin+ and calretinin+ interneurons by investigating changes in mtDNA integrity and quantity within these interneurons. This evidence concerns the gene PVALB and Alpers syndrome.